av Najam Zubair | sep 22, 2022
Business opportunity Production of scalable liver-like tissue that exhibits functionally long-lived human liver characteristics has remained elusive, leaving use of humanoid liver research systems suboptimal. Scientists at the Oslo University Hospital and University...
av Helene Dugstad | sep 20, 2022
Poor persistence of the T-cell product represents an important challenge with CAR-T cell therapy. This is often due to constitutive activity of the CAR leading to T cells exhaustion before a therapeutic effect can be achieved. To address this challenge, an original...
av Aina Rengmark | nov 3, 2021
Business opportunity About 50% of human epidermal growth factor receptor 2 (HER2)-positive tumors express p95HER2, a known constitutively hyperactive truncated version of HER2. This HER2-variant gives aggressive disease, inferior prognosis, and resistance to current...
av Aina Rengmark | sep 16, 2021
Business opportunity Scientists at Oslo University Hospital (Norway) have developed a new chimeric antigen receptor (CAR) targeting STEAP1 positive cells. STEAP1 is expressed in about 90% of prostate cancers, and subgroups of other malignancies, and it is an...
av Mika Falck-Hansen | jan 6, 2021
BUSINESS OPPORTUNITY This new CAR T-cell can be developed to treat children and adults with B cell lymphoma. Inven2 is seeking to out-license the technology to pharmaceutical companies and/or biotechnology SMEs for clinical trials either as a single intervention or...
